MannKind Corporation
MNKDHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeMannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. At a $1.09B market cap, MannKind Corporation ranks as a small-cap company within healthcare. It develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.
Market Cap
$1.09B
Beta
1.04
P/E (TTM)
—
P/E (Fwd)
18.34
EPS (TTM)
$-0.07
EPS (Fwd)
$0.19
ROE
—
ROA
2.0%
Cash
$133.9M
Total Debt
$434.2M
Free CF
$47.0M
52W Change
-20.1%
Annual Financials
Cash vs Debt
MannKind Corporation carries $434.2M in total debt against $133.9M in cash reserves — debt is roughly 3.2x the cash position. Managing this leverage effectively will be important for long-term financial stability. Annual free cash flow of $47.0M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROA of 2.0% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $99.8M (2022) to $349.0M (2025), reflecting a 250% increase over the period.
As with any equity investment, MNKD carries market risk, sector-specific risk, and company-specific risk that investors should evaluate in the context of their own portfolios. No single metric tells the full story. Reviewing MNKD's risk profile alongside its fundamentals and technical indicators provides a more complete picture.